Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...
α-synuclein is a neuronal protein involved in functions like vesicle trafficking and neurotransmitter release. It is typically found in abundance in a healthy brain. However, the aggregation of ...
White arrows indicate accumulation of 18F-SPAL-T-06, suggesting α-synuclein aggregates in the putamen, yellow arrows in the pons, yellow triangle in the cerebellar white matter, and white triangle in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results